TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03307590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Caudal block by dexmedetomidine and bupivavaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal block by bupivavaine alone
Study: NCT02989025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 OHPC
Description: The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
Study: NCT01961180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipralex
Description: the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
Study: NCT03827005

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: InHealth Specialty Pharmacy, Fargo, ND
Study: NCT00440622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
Study: NCT02795676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRX-102 (pegunigalsidase alfa)
Description: PRX-102 1 mg/kg every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: agalsidase beta
Description: agalsidase beta 1 mg/kg every 2 weeks
Study: NCT00943813

Intervention type: BEHAVIORAL
Intervention: video-recording and completing a survey
Description: Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely .
Study: NCT03061903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel
Description: Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device.
Study: NCT05080140

Intervention type: DRUG
Intervention: Ezetimibe 10mg
Description: Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Intervention type: DRUG
Intervention: Ezetimibe 10mg
Description: Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
Study: NCT01961180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03956108

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI+targeted biopsies+Stockholm3-test
Description: MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSA + systematic biopsies
Description: Systematic biopsies and PSA test
Study: NCT00480025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Description: Intramuscular administration, 13 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Intramuscular administration, 13 doses
Study: NCT00373360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil sodium
Description: rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
Study: NCT04391608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching to Tenofovir Alafenamide
Description: Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
Study: NCT04577183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD1 System
Description: The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
Study: NCT02741479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airplane Test
Description: The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airplane Test
Description: The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airplane Test
Description: The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time
Study: NCT04477798

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCT-DIA/MS
Description: PCT-DIA/MS will be validated to classify FNA biopsy specimens
Study: NCT00350181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
Study: NCT03726879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
Study: NCT00350181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 15 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 60 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 60 mg/kg, IV
Study: NCT05080140

Intervention type: DRUG
Intervention: Ezetimibe 10mg
Description: Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
Study: NCT01115062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera Patch
Description: Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
Study: NCT00350181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 60 mg/kg, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTBI
Description: 1320 cGy delivered in 11 120 cGy fractions over 4 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BU
Description: BU 1 mg/kg every 6hr x 4 doses, IV
Study: NCT02763020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit extracts high in polyphenols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit extracts high in polyphenols
Study: NCT01115062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX 4 Cream
Description: LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
Study: NCT02763020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit extracts high in polyphenols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit extracts high in polyphenols

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00724061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2b
Description: PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psoralens with ultraviolet light A
Description: Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrowband-ultraviolet light B
Description: The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
Study: NCT01115062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
Study: NCT04228627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parentral Iron
Description: Correction of Iron stores without anaemia
Study: NCT04107337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocal work session with straw exercises
Description: * Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Vocal work session with open mouth exercises
Description: * Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters.
Study: NCT00774241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75mg/m2 every 3 weeks for 18 weeks
Study: NCT03567460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
Study: NCT03860025

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT02729207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esflurbiprofen Hydrogel Patch
Description: One patch per day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esflurbiprofen Hydrogel Patch
Description: One patch per day for 7 days
Study: NCT03895151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk supplementation
Description: Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Based Recommendation (FBR) nutrition education
Description: Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
Study: NCT01058122

Intervention type: PROCEDURE
Intervention: Collection of adverse drug events
Study: NCT03549897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg Reference Product
Description: 90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg Reference Product
Description: 180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg Test Product
Description: 90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
Study: NCT02658435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 150 mg
Description: Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo 150mg
Description: It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
Study: NCT03977441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Agomelatine or PIacebo
Description: control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine or PIacebo
Description: control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
Study: NCT01638273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
Study: NCT04064827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
Study: NCT04311346

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MR
Description: Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
Study: NCT02293616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate Rich Beetroot Juice
Description: Nitrate rich beetroot juice diet supplement will be consumed by subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02411149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block with Morphine
Description: Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Infiltration
Description: 30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
Study: NCT03161353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta
Description: All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta
Description: All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta
Description: All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.